Welcome to our dedicated page for Scisparc news (Ticker: SPRC), a resource for investors and traders seeking the latest updates and insights on Scisparc stock.
SciSparc Ltd. reports clinical-stage pharmaceutical and intellectual-property developments tied to cannabinoid-based technologies and its majority-owned subsidiary, NeuroThera Labs Inc. The company’s recurring updates cover SCI-110 for Tourette syndrome and Alzheimer’s disease agitation, SCI-210 for autism spectrum disorder and status epilepticus, and combination approaches involving THC, non-psychoactive CBD, PEA and MEAI.
Company news also includes patent activity for CNS, metabolic and antimicrobial-resistance applications; the acquired MUSE™ endoscopic system and related medical-camera intellectual property for GERD procedures; hemp seed oil-based product sales through a controlled subsidiary; and public-company matters such as capital-structure actions, Nasdaq compliance notices, material agreements and financial disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
SciSparc Ltd. (Nasdaq: SPRC) announced the filing of an additional provisional patent application by Clearmind Medicine, focusing on the combination of Clearmind's MEAI and SciSparc's PEA for treating depression. This is part of a collaboration that has already seen three other patent applications filed for MEAI and PEA combinations targeting alcohol use disorder, cocaine addiction, and obesity. Furthermore, six more patents have been filed concerning PEA combined with various psychedelics including LSD and DMT. SciSparc aims to develop therapies for central nervous system disorders, with ongoing programs targeting Tourette Syndrome, Alzheimer's, pain, and autism spectrum disorder (ASD). With a focus on cannabinoid pharmaceuticals, the company is strategically positioned in the emerging psychedelic therapeutic market.
SciSparc Ltd. (NASDAQ: SPRC) has received final approval from the Tel Aviv Sourasky Medical Center for its Phase IIb Clinical Trial of SCI-110, aimed at treating Tourette Syndrome (TS). The trial will assess the drug's efficacy, safety, and tolerability in adults aged 18-65, using a randomized, double-blind, placebo-controlled method. The primary outcomes will be measured using the Yale Global Tic Severity Scale over 12 and 26 weeks. Prof. Tanya Gurevich will lead the trial at the Tel Aviv site, with additional trials planned at Yale University and Hannover Medical School, pending regulatory approvals.
SciSparc Ltd. (Nasdaq: SPRC) announced the closing of a sale of approximately 49% equity in its subsidiary, SciSparc Nutraceuticals Inc., to Jeffs’ Brands Holdings Inc. for a total of $2.5 million and additional payments of around $489,330. The new purchase price for the deal is approximately $3 million. SciSparc will hold around 51% of the subsidiary post-transaction. Under a consulting agreement, Jeffs' Brands will manage the subsidiary's Wellution™ brand for a monthly fee of $20,000, plus a signing bonus of $51,000. Wellution products have achieved significant success on Amazon with numerous positive reviews.